Cipla receives final approval for the generic version of Somatuline® Depot (Lanreotide) Injection 120 mg/ 0.5 mL, 90 mg/0.3 mL, 60 mg/0.2 mL ...Middle East

MUMBAI, India and WARREN, N.J., May 22, 2024 /PRNewswire/ -- Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") and its wholly owned subsidiary Cipla USA Inc., (hereafter referred to as "Cipla"), today announced that it has received the final approval for its...

Hence then, the article about cipla receives final approval for the generic version of somatuline depot lanreotide injection 120 mg 0 5 ml 90 mg 0 3 ml 60 mg 0 2 ml was published today ( Wednesday 22/05/2024 - 10:29 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Cipla receives final approval for the generic version of Somatuline® Depot (Lanreotide) Injection 120 mg/ 0.5 mL, 90 mg/0.3 mL, 60 mg/0.2 mL )

Also on site :

• AI companies are building huge natural gas plants to power data centers. What could go wrong?
• Europe’s cyber agency blames hacking gangs for massive data breach and leak
• The Trump Dictatorship Is Cracking Up